• Home
• About us
• Governance
• Shareholders

Shareholders

Dialogue with shareholders

Financial results are announced on a quarterly basis in April, July, October and February.

The company reports formally to shareholders twice a year, when its half-year and full-year results are announced. The CEO and CFO give presentations on the half-year and full-year results in face-to-face meetings with institutional investors, analysts and the media which are also accessible via web-cast and teleconference. These presentations may be accessed on this site.

The AGM takes place in London and formal notification is sent to shareholders at least one month in advance. At the Meeting a business presentation is made to shareholders and all directors able to attend are available, formally during the Meeting, and informally afterwards, for questions. Committee Chairmen ordinarily attend the AGM to respond to shareholders’ questions.

The results of the voting at the meeting are released to the London Stock Exchange and on this site.

To ensure that the Non-Executive Directors are aware of and understand the views of major shareholders about the company, the Board has in place a briefing process, which is managed by the Chairman, focusing on sector-specific issues as well as general shareholder preferences. With respect to the general perspectives of shareholders, each year the Non-Executive Directors receive an external review of shareholder opinion and presentations from a leading financial analyst specialising in the pharmaceutical sector.

The company’s Investor Relations department, with offices in London and Philadelphia, acts as a focal point for contacts with investors throughout the world.

The CEO, CFO and Chairman maintain a dialogue with institutional shareholders on performance, plans and objectives through a programme of regular meetings. They both speak regularly at external conferences and presentations.